Phase IIa trial launches in advanced pancreatic cancer
The Phase IIa ACCENT trial has launched to explore the activity of focal adhesion kinase (FAK) inhibitor narmafotinib in combination with standard-of-care chemotherapy in advanced pancreatic cancer patients. In November 2023, Amplia Therapeutics announced completion of the Phase Ib stage of the ACCENT trial where ascending… Read More